Gilead Sciences’ (GILD) Hold Rating Reiterated at Needham & Company LLC, Report finds

Gilead Sciences’ (GILD) Hold Rating Reiterated at Needham & Company LLC, Report finds

Gilead Sciences, Inc. (NASDAQ:GILD)‘s stock had its “hold” rating restated by analysts at Needham & Company LLC in a report released on Wednesday.

Other research analysts have also issued reports about the company. Cowen and Company set a $120.00 target price on Gilead Sciences and gave the company a “buy” rating in a research note on Sunday, October 23rd. Maxim Group restated a “hold” rating on shares of Gilead Sciences in a research note on Sunday, November 6th. Citigroup Inc. lowered Gilead Sciences from a “buy” rating to a “neutral” rating and cut their target price for the company from $87.00 to $76.00 in a research note on Wednesday. Wells Fargo & Company restated a “market perform” rating and issued a $65.50 target price (down from $79.50) on shares of Gilead Sciences in a research note on Wednesday. They noted that the move was a valuation call. Finally, Piper Jaffray Companies reiterated a “hold” rating and set a $95.00 price objective (down from $102.00) on shares of Gilead Sciences in a research note on Wednesday. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating, fourteen have assigned a buy rating and two have given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $90.68.

Gilead Sciences (NASDAQ:GILD) traded down 8.61% during midday trading on Wednesday, reaching $66.83. 51,547,414 shares of the company traded hands. The company has a 50-day moving average price of $72.72 and a 200-day moving average price of $75.94. Gilead Sciences has a 12-month low of $65.75 and a 12-month high of $103.10. The company has a market cap of $88.05 billion, a price-to-earnings ratio of 6.18 and a beta of 1.11.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, February 7th. The biopharmaceutical company reported $2.70 EPS for the quarter, beating analysts’ consensus estimates of $2.61 by $0.09. The business earned $7.30 billion during the quarter, compared to analyst estimates of $7.16 billion. Gilead Sciences had a return on equity of 100.57% and a net margin of 47.74%. Gilead Sciences’s revenue was down 13.9% on a year-over-year basis. During the same period in the prior year, the company posted $3.32 earnings per share. On average, analysts predict that Gilead Sciences will post $10.68 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 30th. Stockholders of record on Thursday, March 16th will be paid a dividend of $0.52 per share. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.47. This represents a $2.08 annualized dividend and a dividend yield of 3.11%. The ex-dividend date of this dividend is Tuesday, March 14th. Gilead Sciences’s payout ratio is currently 17.44%.

In other news, Director John W. Madigan sold 105,000 shares of Gilead Sciences stock in a transaction that occurred on Friday, November 18th. The stock was sold at an average price of $74.86, for a total transaction of $7,860,300.00. Following the completion of the transaction, the director now directly owns 121,761 shares in the company, valued at approximately $9,115,028.46. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider John C. Martin sold 73,337 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, January 3rd. The stock was sold at an average price of $73.59, for a total value of $5,396,869.83. Following the transaction, the insider now owns 3,204,433 shares of the company’s stock, valued at $235,814,224.47. The disclosure for this sale can be found here. Insiders own 1.40% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Van Hulzen Asset Management LLC increased its stake in Gilead Sciences by 9.1% in the second quarter. Van Hulzen Asset Management LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 100 shares during the period. Penserra Capital Management LLC increased its stake in Gilead Sciences by 148.3% in the third quarter. Penserra Capital Management LLC now owns 1,296 shares of the biopharmaceutical company’s stock valued at $102,000 after buying an additional 774 shares during the period. Gemmer Asset Management LLC increased its stake in Gilead Sciences by 15.5% in the third quarter. Gemmer Asset Management LLC now owns 1,301 shares of the biopharmaceutical company’s stock valued at $103,000 after buying an additional 175 shares during the period. Lombard Odier Transatlantic Limited Partnership increased its stake in Gilead Sciences by 55.6% in the third quarter. Lombard Odier Transatlantic Limited Partnership now owns 1,400 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 500 shares during the period. Finally, Cable Hill Partners LLC increased its stake in Gilead Sciences by 19.1% in the third quarter. Cable Hill Partners LLC now owns 1,639 shares of the biopharmaceutical company’s stock valued at $125,000 after buying an additional 263 shares during the period. Institutional investors own 74.62% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.

Related posts

Leave a Comment

Gilead Sciences’ (GILD) Hold Rating Reiterated at Needham & Company LLC

Gilead Sciences’ (GILD) Hold Rating Reiterated at Needham & Company LLC

Gilead Sciences, Inc. (NASDAQ:GILD)‘s stock had its “hold” rating restated by analysts at Needham & Company LLC in a report released on Wednesday.

Other research analysts have also issued reports about the company. Cowen and Company set a $120.00 target price on Gilead Sciences and gave the company a “buy” rating in a research note on Sunday, October 23rd. Maxim Group restated a “hold” rating on shares of Gilead Sciences in a research note on Sunday, November 6th. Citigroup Inc. lowered Gilead Sciences from a “buy” rating to a “neutral” rating and cut their target price for the company from $87.00 to $76.00 in a research note on Wednesday. Wells Fargo & Company restated a “market perform” rating and issued a $65.50 target price (down from $79.50) on shares of Gilead Sciences in a research note on Wednesday. They noted that the move was a valuation call. Finally, Piper Jaffray Companies reiterated a “hold” rating and set a $95.00 price objective (down from $102.00) on shares of Gilead Sciences in a research note on Wednesday. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating, fourteen have assigned a buy rating and two have given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $90.68.

Gilead Sciences (NASDAQ:GILD) traded down 8.61% during midday trading on Wednesday, reaching $66.83. 51,547,414 shares of the company traded hands. The company has a 50-day moving average price of $72.72 and a 200-day moving average price of $75.94. Gilead Sciences has a 12-month low of $65.75 and a 12-month high of $103.10. The company has a market cap of $88.05 billion, a price-to-earnings ratio of 6.18 and a beta of 1.11.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, February 7th. The biopharmaceutical company reported $2.70 EPS for the quarter, beating analysts’ consensus estimates of $2.61 by $0.09. The business earned $7.30 billion during the quarter, compared to analyst estimates of $7.16 billion. Gilead Sciences had a return on equity of 100.57% and a net margin of 47.74%. Gilead Sciences’s revenue was down 13.9% on a year-over-year basis. During the same period in the prior year, the company posted $3.32 earnings per share. On average, analysts predict that Gilead Sciences will post $10.68 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 30th. Stockholders of record on Thursday, March 16th will be paid a dividend of $0.52 per share. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.47. This represents a $2.08 annualized dividend and a dividend yield of 3.11%. The ex-dividend date of this dividend is Tuesday, March 14th. Gilead Sciences’s payout ratio is currently 17.44%.

In other news, Director John W. Madigan sold 105,000 shares of Gilead Sciences stock in a transaction that occurred on Friday, November 18th. The stock was sold at an average price of $74.86, for a total transaction of $7,860,300.00. Following the completion of the transaction, the director now directly owns 121,761 shares in the company, valued at approximately $9,115,028.46. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider John C. Martin sold 73,337 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, January 3rd. The stock was sold at an average price of $73.59, for a total value of $5,396,869.83. Following the transaction, the insider now owns 3,204,433 shares of the company’s stock, valued at $235,814,224.47. The disclosure for this sale can be found here. Insiders own 1.40% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Van Hulzen Asset Management LLC increased its stake in Gilead Sciences by 9.1% in the second quarter. Van Hulzen Asset Management LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 100 shares during the period. Penserra Capital Management LLC increased its stake in Gilead Sciences by 148.3% in the third quarter. Penserra Capital Management LLC now owns 1,296 shares of the biopharmaceutical company’s stock valued at $102,000 after buying an additional 774 shares during the period. Gemmer Asset Management LLC increased its stake in Gilead Sciences by 15.5% in the third quarter. Gemmer Asset Management LLC now owns 1,301 shares of the biopharmaceutical company’s stock valued at $103,000 after buying an additional 175 shares during the period. Lombard Odier Transatlantic Limited Partnership increased its stake in Gilead Sciences by 55.6% in the third quarter. Lombard Odier Transatlantic Limited Partnership now owns 1,400 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 500 shares during the period. Finally, Cable Hill Partners LLC increased its stake in Gilead Sciences by 19.1% in the third quarter. Cable Hill Partners LLC now owns 1,639 shares of the biopharmaceutical company’s stock valued at $125,000 after buying an additional 263 shares during the period. Institutional investors own 74.62% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.

Related posts

Leave a Comment